{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:10:37Z","timestamp":1784232637032,"version":"3.55.0"},"reference-count":274,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.intimp.2026.116996","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:00:56Z","timestamp":1781773256000},"page":"116996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Innate immune dysregulation in multiple myeloma: molecular basis and mechanistic interventions"],"prefix":"10.1016","volume":"185","author":[{"given":"Gang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanlin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuming","family":"Zi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.intimp.2026.116996_bb0005","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116996_bb0010","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2141.2008.07547.x","article-title":"Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols","volume":"145","author":"Nair","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116996_bb0020","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00277-022-04783-1","article-title":"Revisiting the impact of immunoglobulin isotypes in multiple myeloma","volume":"101","author":"Bal","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.intimp.2026.116996_bb0025","doi-asserted-by":"crossref","first-page":"1123029","DOI":"10.3389\/fonc.2023.1123029","article-title":"Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories","volume":"13","author":"Gkoliou","year":"2023","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb0030","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"Jama"},{"issue":"9","key":"10.1016\/j.intimp.2026.116996_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0040","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","article-title":"Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.intimp.2026.116996_bb0045","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival","author":"Turesson","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.intimp.2026.116996_bb0050","doi-asserted-by":"crossref","first-page":"1527198","DOI":"10.3389\/fpubh.2025.1527198","article-title":"Global, regional and national epidemiological trends of multiple myeloma from 1990 to 2021: a systematic analysis of the global burden of disease study 2021","volume":"13","author":"Zhuge","year":"2025","journal-title":"Front. Public Health"},{"issue":"10","key":"10.1016\/j.intimp.2026.116996_bb0055","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","article-title":"Multiple myeloma: the (r)evolution of current therapy and a glance into future","volume":"105","author":"Gulla","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0060","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41408-023-00852-4","article-title":"Conditional survival in multiple myeloma and impact of prognostic factors over time","volume":"13","author":"Abdallah","year":"2023","journal-title":"Blood Cancer J."},{"issue":"8","key":"10.1016\/j.intimp.2026.116996_bb0065","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb0075","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab Mafodotin, Bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, Lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116996_bb0085","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb0090","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab Mafodotin, Pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2026.116996_bb0095","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0100","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.intimp.2026.116996_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(24)00176-5","article-title":"Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial","volume":"11","author":"Zhou","year":"2024","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0110","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0115","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12916-025-04086-y","article-title":"Exploring secondary extramedullary myeloma disease: a five-predictor scoring system with spotlight on double-hit cytogenetics","volume":"23","author":"Tao","year":"2025","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0120","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3324\/haematol.2019.219295","article-title":"A real world multicenter retrospective study on extramedullary disease from Balkan myeloma study group and Barcelona university: analysis of parameters that improve outcome","volume":"105","author":"Beksac","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.intimp.2026.116996_bb0125","series-title":"Extramedullary Relapse Post CAR-T","author":"Richard","year":"2022"},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","article-title":"Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial","volume":"17","author":"Xu","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116996_bb0135","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/bloodadvances.2023012354","article-title":"Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications","volume":"8","author":"Letouz\u00e9","year":"2024","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.intimp.2026.116996_bb0140","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0145","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0150","doi-asserted-by":"crossref","first-page":"20846","DOI":"10.1038\/s41598-020-77941-y","article-title":"Quantitative and functional characteristics of circulating and bone marrow PD-1- and TIM-3-positive T cells in treated multiple myeloma patients","volume":"10","author":"Batorov","year":"2020","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.intimp.2026.116996_bb0155","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.116996_bb0160","doi-asserted-by":"crossref","first-page":"1613265","DOI":"10.3389\/fimmu.2025.1613265","article-title":"Deciphering the bone marrow microenvironment\u2019s role in multiple myeloma immunotherapy resistance","volume":"16","author":"Iannozzi","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116996_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101224","article-title":"Contribution of the immune bone marrow microenvironment to tumor growth and bone deconstruction: implications for improving immunotherapeutic strategies in bone metastasis","volume":"69","author":"Massy","year":"2025","journal-title":"Neoplasia"},{"issue":"2","key":"10.1016\/j.intimp.2026.116996_bb0170","article-title":"Adhesion molecules in multiple myeloma oncogenesis and targeted therapy. Int","volume":"11","author":"Bou Zerdan","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb0175","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood.V93.5.1658","article-title":"Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines","volume":"93","author":"Damiano","year":"1999","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.intimp.2026.116996_bb0180","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-12-3676","article-title":"Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance","volume":"19","author":"de Haart","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0185","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41408-024-01172-x","article-title":"Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages","volume":"14","author":"Cheng","year":"2024","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.intimp.2026.116996_bb0190","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1158\/2326-6066.CIR-25-0019","article-title":"Identification of the distinct immune microenvironment features associated with progression following high-dose melphalan and autologous stem cell transplant in multiple myeloma","volume":"13","author":"Sudha","year":"2025","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.116996_bb0195","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/imm.13176","article-title":"V(D)J recombination, somatic hypermutation and class switch recombination of immunoglobulins: mechanism and regulation","volume":"160","author":"Chi","year":"2020","journal-title":"Immunology"},{"issue":"9","key":"10.1016\/j.intimp.2026.116996_bb0200","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1182\/blood-2007-02-069625","article-title":"Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma","volume":"110","author":"Gonz\u00e1lez","year":"2007","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.intimp.2026.116996_bb0205","doi-asserted-by":"crossref","first-page":"13229","DOI":"10.18632\/oncotarget.3644","article-title":"Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma","volume":"6","author":"Cowan","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.intimp.2026.116996_bb0210","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221717","article-title":"Progressive differentiation toward the long-lived plasma cell compartment in the bone marrow","volume":"220","author":"Koike","year":"2023","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2026.116996_bb0215","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/157496","article-title":"Bone marrow microenvironment in multiple myeloma progression","volume":"2012","author":"Manier","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116996_bb0220","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.3324\/haematol.2021.278519","article-title":"2021 European myeloma network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde","volume":"106","author":"Musto","year":"2021","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.intimp.2026.116996_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13235949","article-title":"Genome instability in multiple myeloma: facts and factors","volume":"13","author":"Aksenova","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0230","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","article-title":"Multiple myeloma: signaling pathways and targeted therapy","volume":"5","author":"Lu","year":"2024","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.intimp.2026.116996_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101177","article-title":"MYC alterations in multiple myeloma: genetic insights and prognostic impact","volume":"66","author":"Crist\u00f3bal-Vargas","year":"2025","journal-title":"Neoplasia"},{"issue":"8005","key":"10.1016\/j.intimp.2026.116996_bb0240","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41586-024-07186-6","article-title":"Resilient anatomy and local plasticity of naive and stress haematopoiesis","volume":"627","author":"Wu","year":"2024","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.intimp.2026.116996_bb0245","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.intimp.2026.116996_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116123","article-title":"CD138 and APRIL regulate plasma cell survival, competition, and retention in the bone marrow niche","volume":"44","author":"Park","year":"2025","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.intimp.2026.116996_bb0255","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00018-016-2135-z","article-title":"Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies","volume":"73","author":"Guillerey","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"issue":"4","key":"10.1016\/j.intimp.2026.116996_bb0260","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3324\/haematol.2017.167486","article-title":"Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment","volume":"103","author":"Belloni","year":"2018","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.intimp.2026.116996_bb0265","doi-asserted-by":"crossref","first-page":"14905","DOI":"10.18632\/oncotarget.3614","article-title":"Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes","volume":"6","author":"Alonso","year":"2015","journal-title":"Oncotarget"},{"issue":"23","key":"10.1016\/j.intimp.2026.116996_bb0270","article-title":"Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry. JCI","volume":"3","author":"Oetjen","year":"2018","journal-title":"Insight"},{"issue":"11","key":"10.1016\/j.intimp.2026.116996_bb0275","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/s41375-024-02391-8","article-title":"IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma","volume":"38","author":"Sun","year":"2024","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.intimp.2026.116996_bb0280","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003975","article-title":"Tumor-associated macrophages in multiple myeloma: advances in biology and therapy","volume":"10","author":"Sun","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2026.116996_bb0285","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/ni1136","article-title":"Bone marrow plasmacytoid dendritic cells can differentiate into myeloid dendritic cells upon virus infection","volume":"5","author":"Zuniga","year":"2004","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116996_bb0290","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb0295","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41590-024-01810-3","article-title":"The enduring neutrophil-stroma dance of multiple myeloma","volume":"25","author":"Cerezo-Wallis","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2026.116996_bb0300","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.exphem.2018.06.288","article-title":"Bone marrow eosinophils in plasma cell disorders","volume":"66","author":"Wichert","year":"2018","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.intimp.2026.116996_bb0305","first-page":"4417","article-title":"Eosinophils upregulate PD-L1 and PD-L2 expression to enhance the immunosuppressive microenvironment in multiple myeloma","volume":"130","author":"Driscoll","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.intimp.2026.116996_bb0310","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","article-title":"The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies","volume":"21","author":"Bald","year":"2020","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116996_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020226","article-title":"Alterations of NK cell phenotype in the disease course of multiple myeloma","volume":"13","author":"Pazina","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.116996_bb0320","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3389\/fonc.2014.00348","article-title":"Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities","volume":"4","author":"Botta","year":"2014","journal-title":"Front. Oncol."},{"issue":"7377","key":"10.1016\/j.intimp.2026.116996_bb0325","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1038\/480S48a","article-title":"Microenvironment: Neighbourhood watch","volume":"480","author":"Hughes","year":"2011","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.intimp.2026.116996_bb0330","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031286","article-title":"Multiple myeloma and bone: the fatal interaction","volume":"8","author":"Marino","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0335","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12943-016-0552-0","article-title":"Pharmacological targeting of CXCL12\/CXCR4 signaling in prostate cancer bone metastasis","volume":"15","author":"Conley-LaComb","year":"2016","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.116996_bb0340","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cyto.2018.02.020","article-title":"Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies","volume":"109","author":"Peled","year":"2018","journal-title":"Cytokine"},{"issue":"12","key":"10.1016\/j.intimp.2026.116996_bb0345","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1182\/blood-2014-02-558742","article-title":"CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma","volume":"124","author":"Azab","year":"2014","journal-title":"Blood: J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0350","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/bjh.14807","article-title":"CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma","volume":"179","author":"Waldschmidt","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"24","key":"10.1016\/j.intimp.2026.116996_bb0355","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1182\/blood-2008-12-196618","article-title":"CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling","volume":"113","author":"Levoye","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2026.116996_bb0360","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1046\/j.1365-2141.1999.01762.x","article-title":"Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1","volume":"107","author":"Sanz-Rodr\u00edguez","year":"1999","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0365","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s10238-025-01649-4","article-title":"CD44-downregulation in multiple myeloma inhibits cytoskeleton rearrangement through actin depolymerization","volume":"25","author":"Wang","year":"2025","journal-title":"Clin. Exp. Med."},{"issue":"3","key":"10.1016\/j.intimp.2026.116996_bb0370","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104","article-title":"Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B","volume":"87","author":"Chauhan","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116996_bb0375","series-title":"IL-6, IL-8 and VEGF Neutralisation Restores Drug Sensitivity to Conventional and Novel Treatment Combinations in a Multiple Myeloma Bone Marrow Micro-Environment Model","author":"Maharaj","year":"2012"},{"issue":"2","key":"10.1016\/j.intimp.2026.116996_bb0380","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ni.1981","article-title":"Eosinophils are required for the maintenance of plasma cells in the bone marrow","volume":"12","author":"Chu","year":"2011","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2026.116996_bb0385","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109018","article-title":"Eosinophils and megakaryocytes support the early growth of murine MOPC315 myeloma cells in their bone marrow niches","volume":"9","author":"Wong","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.intimp.2026.116996_bb0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070554","article-title":"Induction of malignant plasma cell proliferation by eosinophils","volume":"8","author":"Wong","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.intimp.2026.116996_bb0395","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1365-2141.2012.09154.x","article-title":"Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells","volume":"158","author":"Kim","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"17","key":"10.1016\/j.intimp.2026.116996_bb0400","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1182\/blood-2009-05-220285","article-title":"Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis","volume":"114","author":"Zheng","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0405","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-018-0614-4","article-title":"Myeloma-derived macrophage inhibitory factor regulates bone marrow stromal cell-derived IL-6 via c-MYC","volume":"11","author":"Piddock","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116996_bb0410","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1158\/1078-0432.CCR-04-2611","article-title":"Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu in vivo model of human multiple myeloma","volume":"11","author":"Tassone","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"26","key":"10.1016\/j.intimp.2026.116996_bb0415","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/blood-2013-12-546374","article-title":"Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma","volume":"123","author":"San-Miguel","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.intimp.2026.116996_bb0420","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9061765","article-title":"Anti-VEGF drugs in the treatment of multiple myeloma patients","volume":"9","author":"Ria","year":"2020","journal-title":"J. Clin. Med."},{"issue":"11","key":"10.1016\/j.intimp.2026.116996_bb0425","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1631\/jzus.B2200277","article-title":"High levels of serum IL-10 indicate disease progression, extramedullary involvement, and poor prognosis in multiple myeloma","volume":"23","author":"Yue","year":"2022","journal-title":"J. Zhejiang Univ. Sci. B"},{"issue":"3","key":"10.1016\/j.intimp.2026.116996_bb0430","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41375-021-01422-y","article-title":"Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression","volume":"36","author":"Dahlhoff","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2026.116996_bb0435","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.620596","article-title":"Treg and oligoclonal expansion of terminal effector CD8(+) T cell as key players in multiple myeloma","volume":"12","author":"Joshua","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb0440","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/0008-5472.CAN-19-0284","article-title":"Runx2 deficiency in osteoblasts promotes myeloma progression by altering the bone microenvironment at new bone sites","volume":"80","author":"Xu","year":"2020","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.116996_bb0445","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1158\/2326-6066.CIR-20-0555","article-title":"The IKZF1-IRF4\/IRF5 Axis controls polarization of myeloma-associated macrophages","volume":"9","author":"Mougiakakos","year":"2021","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb0450","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41590-024-01808-x","article-title":"An IL-1\u03b2-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma","volume":"25","author":"de Jong","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2026.116996_bb0455","doi-asserted-by":"crossref","first-page":"1073227","DOI":"10.3389\/fimmu.2022.1073227","article-title":"Immune dysfunctions affecting bone marrow V\u03b39V\u03b42 T cells in multiple myeloma: role of immune checkpoints and disease status","volume":"13","author":"Giannotta","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116996_bb0460","doi-asserted-by":"crossref","first-page":"1575509","DOI":"10.3389\/fimmu.2025.1575509","article-title":"Dendritic cells in multiple myeloma: from immune evasion to therapeutic potential","volume":"16","author":"Jordan","year":"2025","journal-title":"Front. Immunol."},{"issue":"35","key":"10.1016\/j.intimp.2026.116996_bb0465","doi-asserted-by":"crossref","first-page":"56013","DOI":"10.18632\/oncotarget.10820","article-title":"Multiple myeloma-derived jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche","volume":"7","author":"Colombo","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.intimp.2026.116996_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09167","article-title":"Natural killer cells activity against multiple myeloma cells is modulated by osteoblast-induced IL-6 and IL-10 production","volume":"8","author":"Uhl","year":"2022","journal-title":"Heliyon"},{"issue":"24","key":"10.1016\/j.intimp.2026.116996_bb0475","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1002\/cam4.4814","article-title":"Tumor-associated macrophages regulate the function of cytotoxic T lymphocyte through PD-1\/PD-L1 pathway in multiple myeloma","volume":"11","author":"Zhang","year":"2022","journal-title":"Cancer Med."},{"issue":"20","key":"10.1016\/j.intimp.2026.116996_bb0480","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","author":"G\u00f6rg\u00fcn","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2026.116996_bb0485","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.4049\/jimmunol.1203373","article-title":"Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow","volume":"190","author":"Ramachandran","year":"2013","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116996_bb0490","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/bjh.19049","article-title":"Tumour-derived exosomes promote the induction of monocytic myeloid-derived suppressor cells from peripheral blood mononuclear cells by delivering miR-106a-5p and miR-146a-5p in multiple myeloma","volume":"203","author":"Mizuhara","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116996_bb0495","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-022-00635-3","article-title":"Identification and validation of ecto-5\u2032 nucleotidase as an immunotherapeutic target in multiple myeloma","volume":"12","author":"Ray","year":"2022","journal-title":"Blood Cancer J."},{"issue":"8","key":"10.1016\/j.intimp.2026.116996_bb0500","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081988","article-title":"Harnessing natural killer cells in Cancer immunotherapy: a review of mechanisms and novel therapies","volume":"13","author":"St-Pierre","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.intimp.2026.116996_bb0505","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151031","article-title":"NK cells respond to haptens by the activation of calcium permeable plasma membrane channels","volume":"11","author":"Grandcl\u00e9ment","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.intimp.2026.116996_bb0510","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00251-024-01336-w","article-title":"HLA class I NK-epitopes and KIR diversities in patients with multiple myeloma","volume":"76","author":"Beelen","year":"2024","journal-title":"Immunogenetics"},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0515","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","article-title":"Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0520","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1084\/jem.20181076","article-title":"Inducible down-regulation of MHC class I results in natural killer cell tolerance","volume":"216","author":"Bern","year":"2019","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.116996_bb0525","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.smim.2014.02.007","article-title":"NK cell self tolerance, responsiveness and missing self recognition","volume":"26","author":"Shifrin","year":"2014","journal-title":"Semin. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116996_bb0530","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/eji.202049028","article-title":"Human NK cells, their receptors and function","volume":"51","author":"Quatrini","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2026.116996_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2022.104511","article-title":"Changes in the natural killer cell repertoire and function induced by the cancer immune adjuvant candidate IMMUNEPOTENT-CRP","volume":"374","author":"Lorenzo-Anota","year":"2022","journal-title":"Cell. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116996_bb0540","article-title":"Tumor-treating fields increase cytotoxic degranulation of natural killer cells against cancer cells","volume":"5","author":"Mylod","year":"2024","journal-title":"Cell Rep. Phys. Sci."},{"key":"10.1016\/j.intimp.2026.116996_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104859","article-title":"Metabolic reprogramming of NK cells drives anti-tumor immunity","volume":"215","author":"Yang","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.intimp.2026.116996_bb0550","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jconrel.2024.04.017","article-title":"Co-encapsulation of granzyme B and perforin in nanocapsules for tumour therapy: biomimicking immune cells","volume":"369","author":"Shi","year":"2024","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.intimp.2026.116996_bb0555","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/JLB.MR0718-269R","article-title":"Mechanisms of natural killer cell-mediated cellular cytotoxicity","volume":"105","author":"Prager","year":"2019","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0560","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00251-025-01383-x","article-title":"Dysregulation of lncRNAs in NK cells from breast cancer patients: implications for NK cell functions","volume":"77","author":"Rady","year":"2025","journal-title":"Immunogenetics"},{"issue":"25","key":"10.1016\/j.intimp.2026.116996_bb0565","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood.2024026455","article-title":"The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy","volume":"145","author":"Korst","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2026.116996_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2025.101639","article-title":"Advances in NK cell therapy for multiple myeloma","volume":"38","author":"Liu","year":"2025","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"9","key":"10.1016\/j.intimp.2026.116996_bb0575","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.3324\/haematol.2020.277525","article-title":"Myeloma natural killer cells are exhausted and have impaired regulation of activation","volume":"106","author":"D\u2019Souza","year":"2021","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.intimp.2026.116996_bb0580","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/bloodadvances.2019000953","article-title":"Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules","volume":"4","author":"Barberi","year":"2020","journal-title":"Blood Adv."},{"issue":"17","key":"10.1016\/j.intimp.2026.116996_bb0585","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1182\/bloodadvances.2022007905","article-title":"NK cells CD56bright and CD56dim subset cytokine loss and exhaustion is associated with impaired survival in myeloma","volume":"6","author":"Seymour","year":"2022","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.intimp.2026.116996_bb0590","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1182\/blood.2023023529","article-title":"NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma","volume":"144","author":"Blanquart","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2025.153107","article-title":"Proportional and functional anomalies of CD38(+) NK Cells:A new mechanism for impaired anti-tumour immunity in multiple myeloma?","volume":"230","author":"Chen","year":"2025","journal-title":"Immunobiology"},{"key":"10.1016\/j.intimp.2026.116996_bb0600","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575609","article-title":"Targeting NK cell inhibitory receptors for precision multiple myeloma immunotherapy","volume":"11","author":"Alfarra","year":"2020","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2026.116996_bb0605","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1065","article-title":"Single-cell transcriptome profiling reveals the key role of ZNF683 in natural killer cell exhaustion in multiple myeloma","volume":"12","author":"Li","year":"2022","journal-title":"Clin. Transl. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.116996_bb0610","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/10815589251348915","article-title":"Osteoblasts inhibit NK cell killing function via RANK\/RANKL in multiple myeloma","volume":"74","author":"Meng","year":"2026","journal-title":"J. Investig. Med."},{"key":"10.1016\/j.intimp.2026.116996_bb0615","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41413-018-0040-9","article-title":"RANKL-RANK signaling regulates osteoblast differentiation and bone formation","volume":"6","author":"Cao","year":"2018","journal-title":"Bone Res."},{"issue":"10","key":"10.1016\/j.intimp.2026.116996_bb0620","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1093\/humrep\/deu172","article-title":"An increased level of IL-6 suppresses NK cell activity in peritoneal fluid of patients with endometriosis via regulation of SHP-2 expression","volume":"29","author":"Kang","year":"2014","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.intimp.2026.116996_bb0625","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.3389\/fimmu.2018.01947","article-title":"The cytotoxic activity of natural killer cells is suppressed by IL-10(+) regulatory T cells during acute retroviral infection","volume":"9","author":"Littwitz-Salomon","year":"2018","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189435","article-title":"Osteoblasts in bone metastasis: key players in the tumor microenvironment and therapeutic targets","volume":"1880","author":"Jin","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0635","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12010248","article-title":"CAR NK92 cells targeting BCMA can effectively kill multiple myeloma cells both in vitro and in vivo","volume":"12","author":"Park","year":"2024","journal-title":"Biomedicines"},{"issue":"21","key":"10.1016\/j.intimp.2026.116996_bb0640","doi-asserted-by":"crossref","first-page":"35088","DOI":"10.18632\/oncotarget.17070","article-title":"NK cells and multiple myeloma-associated endothelial cells: molecular interactions and influence of IL-27","volume":"8","author":"Dondero","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2026.116996_bb0645","article-title":"Natural killer cells in the malignant niche of multiple myeloma","volume":"12","author":"Venglar","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116996_bb0650","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/1541-7786.MCR-23-0282","article-title":"Exosomal lncRNA NEAT1 inhibits NK-cell activity to promote multiple myeloma cell immune escape via an EZH2\/PBX1 Axis","volume":"22","author":"Wang","year":"2024","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116996_bb0655","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.21378.1","article-title":"Recent advances in iNKT cell development","volume":"9","author":"Hogquist","year":"2020","journal-title":"F1000 Res."},{"issue":"8","key":"10.1016\/j.intimp.2026.116996_bb0660","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/intimm\/dxae019","article-title":"Recent advances regarding the potential roles of invariant natural killer T cells in cardiovascular diseases with immunological and inflammatory backgrounds","volume":"36","author":"Iwabuchi","year":"2024","journal-title":"Int. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0665","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1038\/s41598-020-60229-6","article-title":"YY1(lo) NKT cells are dedicated IL-10 producers","volume":"10","author":"Darcy","year":"2020","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.intimp.2026.116996_bb0670","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4110\/in.2017.17.6.365","article-title":"Lineage differentiation program of invariant natural killer T cells","volume":"17","author":"Kwon","year":"2017","journal-title":"Immune Netw."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0675","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1038\/s41467-018-05026-6","article-title":"TCR signal strength controls thymic differentiation of iNKT cell subsets","volume":"9","author":"Tuttle","year":"2018","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.intimp.2026.116996_bb0680","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2567.2012.03580.x","article-title":"Strategy of lipid recognition by invariant natural killer T cells: \u2018one for all and all for one\u2019","volume":"136","author":"Mallevaey","year":"2012","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.intimp.2026.116996_bb0685","first-page":"1580","article-title":"Intracellular IL-4 and IFN-\u03b3 expression in iNKT cells from patients with chronic lymphocytic leukemia","volume":"15","author":"Bojarska-Junak","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.intimp.2026.116996_bb0690","article-title":"Adoptive immunotherapy with engineered iNKT cells to target Cancer cells and the suppressive microenvironment","volume":"9","author":"Delfanti","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"issue":"7","key":"10.1016\/j.intimp.2026.116996_bb0695","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1111\/cas.14428","article-title":"Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner","volume":"111","author":"Aoki","year":"2020","journal-title":"Cancer Sci."},{"issue":"21","key":"10.1016\/j.intimp.2026.116996_bb0700","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1158\/1078-0432.CCR-07-5290","article-title":"Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy","volume":"14","author":"Song","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116996_bb0705","series-title":"ATRA Upregulates Cell Surface CD1D on Myeloma Cells and Sensitizes them to INKT Cell-Mediated Lysis","author":"Li","year":"2014"},{"issue":"11","key":"10.1016\/j.intimp.2026.116996_bb0710","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood-2008-06-161281","article-title":"Regulation of multiple myeloma survival and progression by CD1d","volume":"113","author":"Spanoudakis","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0715","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/cei.12196","article-title":"Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy","volume":"175","author":"Chan","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb0720","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1111\/jcmm.13554","article-title":"Deficient invariant natural killer T cells had impaired regulation on osteoclastogenesis in myeloma bone disease","volume":"22","author":"Jiang","year":"2018","journal-title":"J. Cell. Mol. Med."},{"issue":"12","key":"10.1016\/j.intimp.2026.116996_bb0725","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1007\/s00277-024-05820-x","article-title":"Lymphocyte profile in peripheral blood of patients with multiple myeloma","volume":"103","author":"Dekojov\u00e1","year":"2024","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0730","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/oxfordjournals.jbchem.a124504","article-title":"Expression of gangliosides GM3 (NeuAc) and GM3 (NeuGc) in myelomas and hybridomas of mouse, rat, and human origin","volume":"116","author":"M\u00fcthing","year":"1994","journal-title":"J. Biochem."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0735","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2567.2007.02760.x","article-title":"Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand","volume":"123","author":"Park","year":"2008","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.intimp.2026.116996_bb0740","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1172\/JCI59987","article-title":"Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease","volume":"125","author":"Ersek","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb0745","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00262-016-1812-y","article-title":"The tumor antigen N-glycolyl-GM3 is a human CD1d ligand capable of mediating B cell and natural killer T cell interaction","volume":"65","author":"Gentilini","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0750","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/eji.201545725","article-title":"Globotriaosylceramide inhibits iNKT-cell activation in a CD1d-dependent manner","volume":"46","author":"Pereira","year":"2016","journal-title":"Eur. J. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116996_bb0755","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.108","article-title":"Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma","volume":"6","author":"Spanoudakis","year":"2016","journal-title":"Blood Cancer J."},{"issue":"17","key":"10.1016\/j.intimp.2026.116996_bb0760","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1182\/bloodadvances.2022008118","article-title":"Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA","volume":"6","author":"Casey","year":"2022","journal-title":"Blood Adv."},{"issue":"20","key":"10.1016\/j.intimp.2026.116996_bb0765","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1182\/bloodadvances.2023010032","article-title":"Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc","volume":"7","author":"O\u2019Neal","year":"2023","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.intimp.2026.116996_bb0770","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22031096","article-title":"Preclinical evaluation of invariant natural killer T cells modified with CD38 or BCMA chimeric antigen receptors for multiple myeloma","volume":"22","author":"Poels","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0775","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0780","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-cancerbio-042120-105240","article-title":"Myeloid-derived suppressor cells: facilitators of cancer and obesity-induced cancer","volume":"5","author":"Ostrand-Rosenberg","year":"2021","journal-title":"Ann. Rev. Cancer Biol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116996_bb0785","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0790","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2026.116996_bb0795","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jare.2024.07.033","article-title":"Insights of immune cell heterogeneity, tumor-initiated subtype transformation, drug resistance, treatment and detecting technologies in glioma microenvironment","volume":"72","author":"Chen","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.intimp.2026.116996_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154711","article-title":"Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in cancer","volume":"248","author":"Li","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"4","key":"10.1016\/j.intimp.2026.116996_bb0805","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/jleuko\/qiad158","article-title":"Elucidating granulocytic myeloid-derived suppressor cell heterogeneity during Staphylococcus aureus biofilm infection","volume":"115","author":"Bertrand","year":"2024","journal-title":"J. Leukoc. Biol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb0810","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/bjh.16881","article-title":"Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma","volume":"191","author":"Kuwahara-Ota","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb0815","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1158\/2326-6066.CIR-20-0663","article-title":"Myeloma-secreted Galectin-1 potently interacts with CD304 on Monocytic myeloid-derived suppressor cells","volume":"9","author":"Lim","year":"2021","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb0820","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1158\/2326-6066.CIR-21-0242","article-title":"Galectin-1 supports a dangerous liaison between monocytes and multiple myeloma","volume":"9","author":"Ugel","year":"2021","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0825","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10517-022-05651-8","article-title":"Expression of inhibitory molecules (Arginase-1, IDO, and PD-L1) by myeloid-derived suppressor cells in multiple myeloma patients in remission","volume":"174","author":"Tyrinova","year":"2022","journal-title":"Bull. Exp. Biol. Med."},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e26362","article-title":"Decreased circulating myeloid-derived suppressor cell count at the engraftment is one of the risk factors for multiple myeloma relapse after autologous hematopoietic stem cell transplantation","volume":"10","author":"Tyrinova","year":"2024","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.intimp.2026.116996_bb0835","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10517-025-06484-x","article-title":"\u201cHomeostatic\u201d cytokines enhance the expression of PD-1, Tim-3, and their ligands on myeloid cells","volume":"179","author":"Leplina","year":"2025","journal-title":"Bull. Exp. Biol. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0840","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/08820139.2025.2568871","article-title":"PD-1\/TIM-3-expressing myeloid cells during the early immune reconstitution in patients with multiple myeloma after high-dose chemotherapy","volume":"55","author":"Serpeninova","year":"2026","journal-title":"Immunol. Investig."},{"issue":"6","key":"10.1016\/j.intimp.2026.116996_bb0845","article-title":"Associations between myeloid-derived suppressor cells, TIM-3+ T cells, and clinical factors during the post-transplant neutropenia period in patients with multiple myeloma","volume":"17","author":"Batorov","year":"2025","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0850","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008979","article-title":"Depletion of myeloid-derived suppressor cells sensitizes murine multiple myeloma to PD-1 checkpoint inhibitors","volume":"13","author":"Xiong","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2026.116996_bb0855","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4062\/biomolther.2020.131","article-title":"A novel anti-PD-L1 antibody exhibits antitumor effects on multiple myeloma in murine models via antibody-dependent cellular cytotoxicity","volume":"29","author":"Ahn","year":"2021","journal-title":"Biomol. Ther. (Seoul)"},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb0860","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/ijlh.14473","article-title":"Single-cell transcriptome analysis reveals the effect of MIF on myeloid-derived suppressor cells in multiple myeloma","volume":"47","author":"Zhao","year":"2025","journal-title":"Int. J. Lab. Hematol."},{"issue":"14","key":"10.1016\/j.intimp.2026.116996_bb0865","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/1873-3468.70108","article-title":"Rewriting the dendritic cell code in cancer-from subset identity to immunotherapeutic design","volume":"599","author":"Silva Barcelos","year":"2025","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0870","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13046-024-03121-9","article-title":"Plasmacytoid dendritic cells at the forefront of anti-cancer immunity: rewiring strategies for tumor microenvironment remodeling","volume":"43","author":"Monti","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0875","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41392-025-02264-1","article-title":"Pattern recognition receptors: function, regulation and therapeutic potential","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2026.116996_bb0880","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3389\/fimmu.2018.00990","article-title":"Mouse DC-SIGN\/CD209a as target for antigen delivery and adaptive immunity","volume":"9","author":"Schetters","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116996_bb0885","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2023.101848","article-title":"Antigen cross-presentation by dendritic cells: a critical axis in cancer immunotherapy","volume":"71","author":"Moussion","year":"2024","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.intimp.2026.116996_bb0890","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920987056","article-title":"Methotrexate enhances antigen presentation and maturation of tumour antigen-loaded dendritic cells through NLRP3 inflammasome activation: a strategy for dendritic cell-based cancer vaccine","volume":"13","author":"Shi","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"16","key":"10.1016\/j.intimp.2026.116996_bb0895","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10163717","article-title":"Plasmacytoid dendritic cells in patients with MGUS and multiple myeloma","volume":"10","author":"Knight","year":"2021","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.116996_bb0900","article-title":"Enhancing plasmacytoid dendritic cell functionality with all-trans retinoic acid for improved multiple myeloma therapy","volume":"33","author":"Yu","year":"2025","journal-title":"Mol. Ther. Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116996_bb0905","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1172\/JCI121421","article-title":"E-cadherin expression on multiple myeloma cells activates tumor-promoting properties in plasmacytoid DCs","volume":"128","author":"Bi","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2026.116996_bb0910","doi-asserted-by":"crossref","first-page":"1444821","DOI":"10.3389\/fimmu.2024.1444821","article-title":"Type I-conventional dendritic cells support the progression of multiple myeloma in the bone marrow","volume":"15","author":"Suzuki","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116996_bb0915","doi-asserted-by":"crossref","first-page":"1076096","DOI":"10.3389\/fphar.2022.1076096","article-title":"Pomalidomide enhances the maturation of dendritic cells derived from healthy donors and multiple myeloma patients","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116996_bb0920","doi-asserted-by":"crossref","first-page":"1104403","DOI":"10.3389\/fphar.2023.1104403","article-title":"Leonurine promotes the maturation of healthy donors and multiple myeloma patients derived-dendritic cells via the regulation on arachidonic acid metabolism","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116996_bb0925","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2015.11","article-title":"Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells","volume":"29","author":"Ray","year":"2015","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.intimp.2026.116996_bb0930","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139867","article-title":"PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests Benefit of targeted anti PD1-PDL1 therapy","volume":"10","author":"Sponaas","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb0935","article-title":"\u03b2-Catenin in dendritic cells negatively regulates CD8 T cell immune responses through the immune checkpoint molecule Tim-3","volume":"12","author":"Fu","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.intimp.2026.116996_bb0940","doi-asserted-by":"crossref","DOI":"10.1111\/imm.13926","article-title":"Innate immune activation is a strong suppressor of CCL22 and impedes regulatory T cell-dendritic cell interaction","author":"Piseddu","year":"2025","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.intimp.2026.116996_bb0945","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266566","article-title":"SIRP\u03b1 - CD47 axis regulates dendritic cell-T cell interactions and TCR activation during T cell priming in spleen","volume":"17","author":"Autio","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0950","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb0955","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s10753-020-01236-7","article-title":"M1 but not M0 extracellular vesicles induce polarization of RAW264.7 macrophages via the TLR4-NF\u03baB pathway in vitro","volume":"43","author":"Shi","year":"2020","journal-title":"Inflammation"},{"issue":"17","key":"10.1016\/j.intimp.2026.116996_bb0960","doi-asserted-by":"crossref","DOI":"10.3390\/cells13171428","article-title":"Roles of M1 macrophages and their extracellular vesicles in Cancer therapy","volume":"13","author":"Zhou","year":"2024","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.intimp.2026.116996_bb0965","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11306-020-01656-4","article-title":"Metabolic characterisation of THP-1 macrophage polarisation using LC-MS-based metabolite profiling","volume":"16","author":"Abuawad","year":"2020","journal-title":"Metabolomics"},{"issue":"7\u20138","key":"10.1016\/j.intimp.2026.116996_bb0970","first-page":"546","article-title":"Increased glycolytic activity is part of impeded M1(LPS) macrophage polarization in the presence of Urolithin A","volume":"90","author":"Bahiraii","year":"2024","journal-title":"Planta Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0975","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","article-title":"Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance","volume":"8","author":"Wang","year":"2024","journal-title":"NPJ Precis. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb0980","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","article-title":"Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy","volume":"44","author":"Yang","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2026.116996_bb0985","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00262-022-03241-1","article-title":"Interleukin-32\u03b3 promotes macrophage-mediated chemoresistance by inducing CSF1-dependent M2 macrophage polarization in multiple myeloma","volume":"72","author":"Yan","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"22","key":"10.1016\/j.intimp.2026.116996_bb0990","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212118","article-title":"Tumor-derived small extracellular vesicles induce pro-inflammatory cytokine expression and PD-L1 regulation in M0 macrophages via IL-6\/STAT3 and TLR4 signaling pathways","volume":"22","author":"Pucci","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2026.116996_bb0995","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s00262-025-04031-1","article-title":"USP5 motivates immunosuppressive microenvironment in multiple myeloma by activating STAT2-PFKFB4-mediated glycolysis","volume":"74","author":"Long","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"issue":"8","key":"10.1016\/j.intimp.2026.116996_bb1000","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/apm.13306","article-title":"Multiple myeloma cell-derived exosomes promote favorable tumor functional performance by polarizing macrophages toward M2-like cells","volume":"131","author":"Razi","year":"2023","journal-title":"Apmis"},{"issue":"11","key":"10.1016\/j.intimp.2026.116996_bb1005","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s12032-020-01426-1","article-title":"Synergistic effects of multiple myeloma cells and tumor-associated macrophages on vascular endothelial cells in vitro","volume":"37","author":"Sun","year":"2020","journal-title":"Med. Oncol."},{"key":"10.1016\/j.intimp.2026.116996_bb1010","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106709","article-title":"Tumor-associated macrophages modulate angiogenesis and tumor growth in a xenograft mouse model of multiple myeloma","volume":"110","author":"Sun","year":"2021","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb1015","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41419-021-03748-y","article-title":"BMI1 regulates multiple myeloma-associated macrophage\u2019s pro-myeloma functions","volume":"12","author":"Zhang","year":"2021","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb1020","doi-asserted-by":"crossref","DOI":"10.1002\/pgr2.1","article-title":"Extracellular vesicles released during hypoxia transport heparanase and enhance macrophage migration, endothelial tube formation and cancer cell stemness","volume":"1","author":"Tripathi","year":"2023","journal-title":"Proteoglycan Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb1025","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12885-024-11945-z","article-title":"Prognostic marker CD27 and its micro-environmental in multiple myeloma","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb1030","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1007\/s12672-025-03312-6","article-title":"Targeting the CD47-SIRPalpha checkpoint in multiple myeloma","volume":"16","author":"Sim","year":"2025","journal-title":"Discov. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb1035","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000881","article-title":"NK cell phenotype is associated with response and resistance to Daratumumab in relapsed\/refractory multiple myeloma","volume":"7","author":"Verkleij","year":"2023","journal-title":"Hemasphere"},{"issue":"10","key":"10.1016\/j.intimp.2026.116996_bb1040","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-20-3418","article-title":"Adaptive natural killer cells facilitate effector functions of Daratumumab in multiple myeloma","volume":"27","author":"Cho","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116996_bb1045","doi-asserted-by":"crossref","first-page":"1102471","DOI":"10.3389\/fimmu.2022.1102471","article-title":"The immune suppressive tumor microenvironment in multiple myeloma: the contribution of myeloid-derived suppressor cells","volume":"13","author":"Giannotta","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb1050","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-024-01019-5","article-title":"A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death","volume":"14","author":"Ray","year":"2024","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb1055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000610","article-title":"Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade","volume":"8","author":"Yang","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb1060","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/imr.12732","article-title":"Plasma cells: you are what you eat","volume":"288","author":"D\u2019Souza","year":"2019","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2026.116996_bb1065","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/14728222.2017.1279148","article-title":"The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma","volume":"21","author":"Giuliani","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb1070","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-01-690743","article-title":"Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target","volume":"128","author":"Bolzoni","year":"2016","journal-title":"Blood: J. Am. Soc. Hematol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116996_bb1075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/imm.12777","article-title":"Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes","volume":"152","author":"Allison","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2026.116996_bb1080","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3389\/fimmu.2017.00367","article-title":"What fuels natural killers? metabolism and NK cell responses","volume":"8","author":"Gardiner","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116996_bb1085","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3389\/fimmu.2018.00445","article-title":"Phosphoinositide-3-kinase signaling in human natural killer cells: new insights from primary immunodeficiency","volume":"9","author":"Mace","year":"2018","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb1090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064835","article-title":"Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells","volume":"8","author":"Sarkar","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.intimp.2026.116996_bb1095","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1062968","article-title":"Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-\u03b2 and miR23a transfer","volume":"5","author":"Berchem","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2026.116996_bb1100","doi-asserted-by":"crossref","first-page":"1359084","DOI":"10.3389\/fcell.2024.1359084","article-title":"Natural killer cells affect the natural course, drug resistance, and prognosis of multiple myeloma","volume":"12","author":"Zhang","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"issue":"13","key":"10.1016\/j.intimp.2026.116996_bb1105","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb1110","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.intimp.2026.116996_bb1115","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.bbmt.2011.03.011","article-title":"Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade","volume":"17","author":"Hallett","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"10","key":"10.1016\/j.intimp.2026.116996_bb1120","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.intimp.2026.116996_bb1125","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s11596-023-2747-0","article-title":"Lactate decreases bortezomib sensitivity and predicts poor clinical outcomes of multiple myeloma","volume":"43","author":"Ma","year":"2023","journal-title":"Curr. Med. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2026.116996_bb1130","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13388","article-title":"Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma","volume":"56","author":"Barbato","year":"2023","journal-title":"Cell Prolif."},{"issue":"4","key":"10.1016\/j.intimp.2026.116996_bb1135","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/path.4860","article-title":"Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation","volume":"241","author":"De Beule","year":"2017","journal-title":"J. Pathol."},{"issue":"12","key":"10.1016\/j.intimp.2026.116996_bb1140","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41590-018-0226-8","article-title":"Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages","volume":"19","author":"Bohn","year":"2018","journal-title":"Nat. Immunol."},{"issue":"22","key":"10.1016\/j.intimp.2026.116996_bb1145","doi-asserted-by":"crossref","first-page":"35863","DOI":"10.18632\/oncotarget.16262","article-title":"Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells","volume":"8","author":"Thompson","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2026.116996_bb1150","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101100","article-title":"Proteasome inhibition in combination with immunotherapies: state-of-the-art in multiple myeloma","volume":"61","author":"Kegyes","year":"2023","journal-title":"Blood Rev."},{"issue":"3","key":"10.1016\/j.intimp.2026.116996_bb1155","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2015.223","article-title":"Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives","volume":"30","author":"Lonial","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb1160","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"3","key":"10.1016\/j.intimp.2026.116996_bb1165","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","article-title":"International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","volume":"39","author":"Costa","year":"2025","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.intimp.2026.116996_bb1170","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.intimp.2026.116996_bb1175","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12288-025-02008-9","article-title":"Approaches to managing relapsed myeloma: switching drug class or retreatment with same drug class?","volume":"41","author":"Vijjhalwar","year":"2025","journal-title":"Indian J. Hematol. Blood Transfus."},{"issue":"2","key":"10.1016\/j.intimp.2026.116996_bb1180","article-title":"Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma","volume":"3","author":"Nahi","year":"2022","journal-title":"Cell Rep. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.116996_bb1185","article-title":"Autologous cellular therapy for myeloma: giving ex vivo expanded NK cells their due","volume":"3","author":"Shapiro","year":"2022","journal-title":"Cell Rep. Med."},{"issue":"8","key":"10.1016\/j.intimp.2026.116996_bb1190","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","volume":"141","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2026.116996_bb1195","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030577","article-title":"Optimizing the procedure to manufacture clinical-grade NK cells for adoptive immunotherapy","volume":"13","author":"Fern\u00e1ndez","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.intimp.2026.116996_bb1200","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41423-021-00808-3","article-title":"Advances in NK cell production","volume":"19","author":"Fang","year":"2022","journal-title":"Cell. Mol. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116996_bb1205","doi-asserted-by":"crossref","DOI":"10.3390\/cells10050967","article-title":"Selection, expansion, and unique pretreatment of allogeneic human natural killer cells with anti-CD38 monoclonal antibody for efficient multiple myeloma treatment","volume":"10","author":"Motais","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2026.116996_bb1210","doi-asserted-by":"crossref","first-page":"1275076","DOI":"10.3389\/fonc.2023.1275076","article-title":"Adoptive NK cell therapy - a Beacon of Hope in multiple myeloma treatment","volume":"13","author":"Vu","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb1215","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s40164-023-00461-8","article-title":"Single VHH-directed BCMA CAR-NK cells for multiple myeloma","volume":"12","author":"Ren","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.116996_bb1220","doi-asserted-by":"crossref","first-page":"5562630","DOI":"10.1155\/2021\/5562630","article-title":"Selective cytotoxicity of single and dual anti-CD19 and anti-CD138 chimeric antigen receptor-natural killer cells against hematologic malignancies","volume":"2021","author":"Luanpitpong","year":"2021","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.intimp.2026.116996_bb1225","doi-asserted-by":"crossref","DOI":"10.1177\/2058739218788968","article-title":"The research significance of concomitant use of CAR-CD138-NK and CAR-CD19-NK to target multiple myelomas","volume":"16","author":"Zhao","year":"2018","journal-title":"Eur. J. Inflammation."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb1230","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2546443","article-title":"Divergent on-target off-tumor effects by CAR T and CAR NK cells suggest different efficacy and safety of cell therapies","volume":"14","author":"Schindler-Wnek","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2026.116996_bb1235","doi-asserted-by":"crossref","first-page":"1533044","DOI":"10.3389\/fimmu.2025.1533044","article-title":"Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expression","volume":"16","author":"Jo","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116996_bb1240","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1271807","article-title":"Immunomodulation of NK, NKT and B\/T cell subtypes in relapsed\/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival","volume":"13","author":"Prabhala","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb1245","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41375-020-0810-4","article-title":"Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting","volume":"35","author":"Viola","year":"2021","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.intimp.2026.116996_bb1250","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-20-1781","article-title":"Immunomodulation in Pomalidomide, dexamethasone, and Daratumumab-treated patients with relapsed\/refractory multiple myeloma","volume":"26","author":"Pierceall","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116996_bb1255","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.actbio.2022.04.029","article-title":"Gold-seaurchin based immunomodulator enabling photothermal intervention and \u03b1CD16 transfection to boost NK cell adoptive immunotherapy","volume":"146","author":"Lin","year":"2022","journal-title":"Acta Biomater."},{"issue":"19","key":"10.1016\/j.intimp.2026.116996_bb1260","doi-asserted-by":"crossref","first-page":"22213","DOI":"10.1021\/acsami.1c03709","article-title":"Lymph node delivery strategy enables the activation of cytotoxic T lymphocytes and natural killer cells to augment Cancer immunotherapy","volume":"13","author":"Jiang","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"2","key":"10.1016\/j.intimp.2026.116996_bb1265","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23020904","article-title":"Dendritic cell-based immunotherapy in multiple myeloma: challenges, opportunities, and future directions","volume":"23","author":"Verheye","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116996_bb1270","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/978-1-0716-4742-4_11","article-title":"Production of mRNA-loaded dendritic cell Cancer vaccines","volume":"2965","author":"H\u00f8nn\u00e5shagen","year":"2025","journal-title":"Methods Mol. Biol."},{"issue":"23","key":"10.1016\/j.intimp.2026.116996_bb1275","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1158\/1078-0432.CCR-23-0235","article-title":"Randomized phase II trial of dendritic cell\/myeloma fusion vaccine with lenalidomide maintenance after upfront autologous hematopoietic cell transplantation for multiple myeloma: BMT CTN 1401","volume":"29","author":"Chung","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.intimp.2026.116996_bb1280","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1158\/1078-0432.CCR-22-3987","article-title":"Survivin dendritic cell vaccine safely induces immune responses and is associated with durable disease control after autologous transplant in patients with myeloma","volume":"29","author":"Freeman","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116996_bb1285","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101413","article-title":"Novel IL-15 dendritic cells have a potent immunomodulatory effect in immunotherapy of multiple myeloma","volume":"20","author":"Chu","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.intimp.2026.116996_bb1290","article-title":"Identification of CD8(+) T-cell epitope from multiple myeloma-specific antigen AKAP4","volume":"13","author":"Ma","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb1295","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00262-020-02654-0","article-title":"Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma","volume":"70","author":"Chu","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2026.116996_bb1300","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.canlet.2020.03.013","article-title":"Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer","volume":"479","author":"Takeyama","year":"2020","journal-title":"Cancer Lett."},{"issue":"14","key":"10.1016\/j.intimp.2026.116996_bb1305","article-title":"Multifunctional Nanodrug mediates synergistic photodynamic therapy and MDSCs-targeting immunotherapy of Colon Cancer","volume":"8","author":"Ding","year":"2021","journal-title":"Adv. Sci. (Weinh)"},{"issue":"6","key":"10.1016\/j.intimp.2026.116996_bb1310","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.4049\/jimmunol.2000500","article-title":"Asah2 represses the p53-Hmox1 Axis to protect myeloid-derived suppressor cells from ferroptosis","volume":"206","author":"Zhu","year":"2021","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116996_bb1315","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2025.153119","article-title":"ATP-NLRP3 inflammasome axis enhances the immunosuppressive effect of myeloid-derived suppressor cells","volume":"230","author":"Ando","year":"2025","journal-title":"Immunobiology"},{"key":"10.1016\/j.intimp.2026.116996_bb1320","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.biomaterials.2017.01.004","article-title":"Exosome-SIRP\u03b1, a CD47 blockade increases cancer cell phagocytosis","volume":"121","author":"Koh","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.intimp.2026.116996_bb1325","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216660","article-title":"Delivery of CD47-SIRP\u03b1 checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma","volume":"585","author":"Lu","year":"2024","journal-title":"Cancer Lett."},{"issue":"8","key":"10.1016\/j.intimp.2026.116996_bb1330","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101129","article-title":"Luteolin promotes macrophage-mediated phagocytosis by inhibiting CD47 pyroglutamation","volume":"14","author":"Li","year":"2021","journal-title":"Transl. Oncol."},{"issue":"Pt 1","key":"10.1016\/j.intimp.2026.116996_bb1335","article-title":"Palmitic acid inhibits macrophage-mediated chemotherapy resistance in multiple myeloma via ALOX12 signaling","volume":"143","author":"Dong","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116996_bb1340","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41577-024-01014-8","article-title":"Short-chain fatty acids: linking diet, the microbiome and immunity","volume":"24","author":"Mann","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb1345","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40168-020-00854-5","article-title":"Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria","volume":"8","author":"Jian","year":"2020","journal-title":"Microbiome"},{"issue":"3","key":"10.1016\/j.intimp.2026.116996_bb1350","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2015-04-574392","article-title":"The human microbiome in hematopoiesis and hematologic disorders","volume":"126","author":"Manzo","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2026.116996_bb1355","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1158\/1078-0432.CCR-23-0195","article-title":"Short-chain fatty acid production by gut microbiota predicts treatment response in multiple myeloma","volume":"30","author":"Rodr\u00edguez-Garc\u00eda","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.intimp.2026.116996_bb1360","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13133885","article-title":"Microbiota-derived short-chain fatty acids boost antitumoral natural killer cell activity","volume":"13","author":"P\u00e9rez","year":"2024","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb1365","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1038\/s41467-018-07305-8","article-title":"Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression","volume":"9","author":"Calcinotto","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2026.116996_bb1370","doi-asserted-by":"crossref","first-page":"2609455","DOI":"10.1080\/19490976.2025.2609455","article-title":"Clostridium butyricum alleviates multiple myeloma by remodeling the bone marrow microenvironment and inhibiting PI3K\/AKT pathway through the gut\u2013bone axis","volume":"18","author":"Wang","year":"2026","journal-title":"Gut Microbes"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926008428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926008428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:37:59Z","timestamp":1784230679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926008428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":274,"alternative-id":["S1567576926008428"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116996","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innate immune dysregulation in multiple myeloma: molecular basis and mechanistic interventions","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116996"}}